Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04710628
Title Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedSIR
Indications

thymic carcinoma

thymoma

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries ITA | FRA | ESP


No variant requirements are available.